Abstract
Background Hallucinations negatively impact quality of life in Parkinson’s disease, yet their neural mechanisms remain poorly understood, particularly in early disease stages. This study aimed to identify functional connectivity differences associated with visual hallucinations in early Parkinson’s Disease and to validate these findings across independent datasets.
Methods Resting state fMRI data from two prior independent studies was used (total N=185; N=84 hallucinators and N=101 non-hallucinators). Group differences in functional connectivity were assessed within predefined cytoarchitectonic cortical classes and functional networks, followed by whole-brain analysis using Network-Based Statistics (NBS). Associations with clinical measures, including hallucination severity, motor symptoms, cognition, and attention, were also evaluated.
Results NBS identified a subnetwork of reduced functional connectivity in hallucinators, connecting regions involved in the default mode, somatomotor and attentional networks. This subnetwork was replicated in a matched sample from our independent cohort (N=50; p<0.01). Functional connectivity within the identified network was significantly associated with hallucination severity (R² = 0.35, p = 0.01), and with baseline and future motor symptoms, cognition, and attention in hallucinators.
Conclusions The identified functional subnetwork shows promise as a potential biomarker and therapeutic target for Parkinson’s disease psychosis, warranting further investigation and validation in future studies.
Competing Interest Statement
ETB serves as a consultant for Sosei Heptares, Boehringer Ingelheim, GlaxoSmithKline, Monument Therapeutics and SR One. M.Mehta works in an advisory capacity for Boehringer Ingleheim, SoseiHeptares and Quolet Industries. The other authors report no competing interests.
Funding Statement
No specific funding was provided for this project. The overall funding bodies for each of the authors are as follows: Marcella Montagnese was supported during her PhD work by the NIHR Maudsley Biomedical Research Centre. This paper represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. J-P. Taylor and M. Firbank are supported by the NIHR Newcastle Biomedical Research Centre (BRC) based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. RA Lawson is supported by a Janet Owens Parkinsons UK Senior Research Fellowship (F-1801). M. A. Mehta is funded by the Research England. His current research is supported by grants from the Medical Research Council (UK), Alzheimers Research UK, NIHR, Wellcome Trust, Lundbeck and SoseiHeptares. D. ffytche was funded by the NIHR Programme Grants for Applied Research (SHAPED: RP- PG-0610-10100). E. Bullmore was supported by an NIHR Senior Investigator award and the Wellcome Trust collaborative award for the Neuroscience in Psychiatry Network. S.E. Morgan was supported by the Accelerate Programme for Scientific Discovery funded by Schmidt Futures
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No new data was generated. PPMI data, downloaded on 05/10/2021, can be accessed at www.ppmi-info.org, and ICICLE-PD data is available by contacting the study lead at Newcastle University (http://bam-ncl.co.uk/our-work/studies/icicle-pd/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All analyses used publicly available packages and code, available at: https://github.com/marcellamontagnese/PDPrestingfMRI. No new data was generated. PPMI data, downloaded on 05/10/2021, can be accessed at www.ppmi-info.org, and ICICLE-PD data is available by contacting the study lead at Newcastle University (http://bam-ncl.co.uk/our-work/studies/icicle-pd/).
Abbreviations
- PDP
- Parkinson’s Disease Psychosis;
- VH
- Visual Hallucinations;
- FC
- Functional Connectivity;
- PDVH
- Parkinson’s Disease with Hallucinations;
- PDNOVH
- Parkinson’s Disease without Hallucinations;
- PPMI
- Parkinson’s Progression Markers Initiative;
- ICICLE
- Incidence of Cognitive Impairments in Cohorts with Longitudinal Evaluation.
